BSE Live
Mar 20, 16:01Prev. Close
4723.10
Open Price
4788.00
Bid Price (Qty.)
4708.00 (2)
Offer Price (Qty.)
4836.00 (6)
NSE Live
Mar 20, 15:49Prev. Close
4724.50
Open Price
4729.00
Bid Price (Qty.)
4773.50 (1)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Pfizer (in Rs. Cr.) | Nov 04 | |
| 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 94.06 | |
| Net CashFlow From Operating Activities | 87.28 | |
| Net Cash Used In Investing Activities | -68.50 | |
| Net Cash Used From Financing Activities | -14.71 | |
| Foreign Exchange Gains / Losses | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 4.07 | |
| Cash And Cash Equivalents Begin of Year | 22.00 | |
| Cash And Cash Equivalents End Of Year | 26.07 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth